> Details

Martinez Lago, Nieves; Covela Rúa, Marta; Brozos Vazquez, Elena; Fernandez Montes, Ana Fernandez; De La Camara Gomez, Juan Cruz; Méndez Méndez, Carlos; Jorge Fernández, Mónica; Cousillas Castiñeira, Antia; Suárez, Begoña Graña; Quintero Aldana, Guillermo Alfonso; Candamio Folgar, Sonia; Salgado Fernandez, Mercedes; Pellon Augusto, Maria Luz; Gonzalez Villarroel, Paula; Gallardo Martin, Elena; Carmona Campos, Marta; Vazquez Rivera, Francisca; Grande Ventura, Carlos; Carral Maseda, Alberto; Reboredo Lopez, Margarita

What is the role of the anti-angiogenic therapy in BRAF (V600E) mutant metastatic colorectal cancer patients in a real-world setting?

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: What is the role of the anti-angiogenic therapy in BRAF (V600E) mutant metastatic colorectal cancer patients in a real-world setting?
  • Contributor: Martinez Lago, Nieves; Covela Rúa, Marta; Brozos Vazquez, Elena; Fernandez Montes, Ana Fernandez; De La Camara Gomez, Juan Cruz; Méndez Méndez, Carlos; Jorge Fernández, Mónica; Cousillas Castiñeira, Antia; Suárez, Begoña Graña; Quintero Aldana, Guillermo Alfonso; Candamio Folgar, Sonia; Salgado Fernandez, Mercedes; Pellon Augusto, Maria Luz; Gonzalez Villarroel, Paula; Gallardo Martin, Elena; Carmona Campos, Marta; Vazquez Rivera, Francisca; Grande Ventura, Carlos; Carral Maseda, Alberto; Reboredo Lopez, Margarita
  • Published: American Society of Clinical Oncology (ASCO), 2019
  • Published in: Journal of Clinical Oncology, 37 (2019) 4_suppl, Seite 620-620
  • Language: English
  • DOI: 10.1200/jco.2019.37.4_suppl.620
  • ISSN: 0732-183X; 1527-7755
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: 620 Background: Activating B-type Raf kinase (BRAF) mutations, mostly missense V600E, occur in approximately 8% to 12% of patients with metastatic colorectal cancer (mCRC). BRAF (V600E)mt is a strong predictor of a poor prognosis, with distinct clinical and pathological features. However, it is unknown whether this mutation is predictive of any treatment benefit in a real world setting. Methods: We conducted an observational, retrospective, multicentric study of patients with BRAF V600E-mt mCRC treated at nine university Spanish hospitals in NW Spain, belonging to GITuD (Galician Research Group on Digestive Tumors). Demographic, clinic and pathological characteristics, overall survival (OS) and first-line progression free survival (PFS) were retrospectively collected and analyzed. Results: Data from 65 patients treated between November 2010 to June 2018 were recorded in this study. Median age was 62.8 years (range 30-83 years), 55.4 % female, 75.4% ECOG PS0-1, 49.2% right-sided, 35.2% high grade, 69.2% synchronous presentation, 66.2% primary tumor resection and median metastatic locations was 2 (range 1-5). With a median follow up of 64.6 months, median OS was 12.9 months (95% CI, 9.8-16.0 months) and first line PFS was 4.1 months (95% CI, 2.7-5.5 months). First line PFS according treatment: Bev+Triplet-CT/Bev+Doublet-CT/antiEGFR+Doublet-CT/Doublet-CT: 6.2 vs 4.8 vs 2.9 vs 2.1 months (p = 0.020). Bevacizumab based chemotherapy was associated with a prolonged first line PFS (median 5.0 vs. 2.1 months, HR, 0.406; 95% CI, 0.20-0.81; p = 0.005). Nevertheless, no statistical differences between bevacizumab based regimes, (Triplet-CT vs Doublet-CT (HR 0.830; 95% CI 0.4-1.9; p = 0.666)) or between Doublet-CT with or without a antiEGFR were found (HR 0.511; 95% CI 0.2-1.6; p = 0.223). Conclusions: Our study confirms the negative prognostic impact of BRAF V600Emt in mCRC and encourage the use of anti-angiogenic based chemotherapy in this subgroup of patients.
  • Access State: Open Access